Ability Pharmaceuticals

Ability Pharmaceuticals is a clinical stage drug discovery and development biopharmaceutical company headquartered in Bellaterra (Barcelona), Catalonia, Spain. Ability Pharmaceuticals develops safer human therapeutics to treat cancer and other indications with unmet medical needs characterized by blockbuster potential, lower risk of drug development failure and lower development costs (fast track review), very high pricing with low cost of goods and low promotional costs in few specialized physicians and centers. Ability Pharmaceuticals currently focuses its development efforts in the treatment of lung cancer and pancreatic cancer, two of the most deadly cancer types and where significant therapeutic improvements need to be done. Lung cancer accounts for 12% of all cancers; however, lung cancer causes 30% of all cancer deaths. 42% of patients survive after one year, but only 15% survive after 5 years. Non-small cell lung carcinoma (NSCLC) accounts for the 25% of all drugs sales for cancer treatment. Pancreatic cancer, although it is the 10th type of cancer, has an extremely high mortality (less than 5% of patients survive after 2 years), holding the 6th position as cause of death among cancers.